Summary of COVID-19 vidofludimus calcium studies

1. Vehreschild et al., Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial

220 patient vidofludimus calcium late treatment RCT: no change in mortality (p=1), no change in ventilation (p=1), and no change in progression (p=1).
RCT 223 hospitalized COVID-19 patients showing no significant difference in mortality, ventilation, or progression with vidofludimus calcium (a DHODH inhibitor) versus placebo.
Oct 2022, Infectious Diseases and Therapy, https://link.springer.com/10.1007/s40121-022-00690-0, https://c19p.org/vehreschild